Becton, Dickinson and Company and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, announced a framework collaboration agreement to enable and facilitate robotic arm integration with BD flow cytometry instruments to accelerate drug discovery and development. Together, the companies intend to develop new software capabilities within BD flow cytometer instrument software to be compatible with Biosero’s Green Button Go software, as well as jointly support biopharmaceutical and contract research organizations with their custom research needs, to enable easy integration with robotic arms.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target lowered to $278 from $312 at Barclays
- Becton Dickinson announces additional investments in manufacturing
- Becton Dickinson announces BD Onclarity HPV Assay added to ASCCP guidelines
- Becton Dickinson Appoints New Chief Accounting Officer
- Becton Dickinson names Pamela Spikner chief accounting officer